GlassScriptPhysician profile
Ian David Kirchner
NPI 1639583859
$1,950.19
in general payments reported to CMS, 2019-2025
20 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $17.64 · 2021: $78.12 · 2022: $278 · 2023: $463 · 2024: $369 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $511.44 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Abbvie INC. | $370.27 | 2022-2025 | |
| Alcon Vision LLC | $330.37 | 2019-2025 | Tryptyr, Rocklatan, Eysuvis |
| Bausch & Lomb Americas INC. | $153.21 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sight Sciences, INC. | $92.85 | 2021-2023 | Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $89.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $89.54 | 2022 | |
| Amgen INC. | $43.56 | 2024 | Tepezza |
| Ivantis, INC | $39.01 | 2021 | |
| Allergan, INC. | $32.07 | 2019 | |
| Iridex Corporation | $29.51 | 2022-2024 | |
| Glaukos Corporation | $25.63 | 2019 | |
| Dompe US, INC. | $23.30 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $21.63 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $19.77 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $18.12 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.79 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.74 | 2022 | |
| Omeros Corporation | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Kirchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.